Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Escalation and Expanded Cohort Study of P-MUC1C-ALLO1 in Adult Subjects With Advanced or Metastatic Solid Tumors

NCT05239143 is registered in ClinicalTrials.gov with Poseida Therapeutics, Inc. as lead sponsor.

NCT NCT05239143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05239143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Escalation and Expanded Cohort Study of P-MUC1C-ALLO1 in Adult Subjects With Advanced or Metastatic Solid Tumors
Lead sponsor
Poseida Therapeutics, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
February 15, 2022
Completion date
April 30, 2039
Enrollment
180 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colorectal cancer, gastric cancer, head and neck squamous cell carcinoma, nasopharyngeal cancer, non small cell lung cancer, ovarian cancer, pancreatic cancer, renal cell carcinoma